Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Many insurance plans explicitly exclude weight loss medications, period
Forgive me for the strong language, but theres just no better way to put it
Retatrutide is in Phase 3 clinical trials through Eli Lilly, and cagrilintide is in Phase 3 trials through Novo Nordisk (both as monotherapy and as part of CagriSema)
PlexusDx Precision Peptide Genetic Test ($298) analyzes variants in GIPR, FTO, and MC4R, and 10 other pathways affecting 49 peptides
Retatrutide has generated significant and rapidly expanding research interest as the first tri-receptor incretin agonist to reach advanced pre-clinical and clinical investigation: Triple Receptor Mechanism: Research has characterised Retatrutides balanced activity across GLP-1R, GIPR, and GCGR, with studies documenting its receptor binding affinities, downstream signalling characteristics at each receptor, and the combined metabolic profile produced by tri-agonist co-stimulation confirming a pharmacological profile that is fundamentally broader than any dual or single-receptor compound
